Expect Buzz About Rebyota Fecal Product for C. diff

March 2023

New Rx Rebyota will be the first FDA-approved fecal microbiota product for preventing C. difficile recurrence in adults.

It seems unappealing, but a fecal transplant can help restore a healthy GI flora...or “microbiota.”

Save fecal transplants for a patient who has 3 or more C. diff episodes despite treatment...or possibly for any case of severe, refractory C. diff when antibiotics don’t work at all.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

COPD Clarify the Role of Combo Inhalers for COPD
COVID-19 Share the Latest About COVID-19 Treatments
Immunizations Navigate Pneumococcal Vaccines for Adults
Substance Use Disorder Improve Access to Buprenorphine for Opioid Use Disorder
Pregnancy Don’t Rely On Meds for Cough and Cold in Pregnancy
Infectious Diseases Expect Buzz About Rebyota Fecal Product for C. diff
PCOS Tailor PCOS Treatment Based on Symptoms
Med Administration Limit Complications When Giving Meds Via Feeding Tubes
Hair Loss Answer Questions About Female Pattern Hair Loss
Poison Prevention Provide Strategies to Prevent Poisonings
Surgery Revisit Meds in “Enhanced Recovery After Surgery” Protocols

Expect Buzz About Rebyota Fecal Product for C. diff

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents